HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Larramendy-Gozalo, C. Articles by Deslys, J.-P. Search for Related Content PubMed PubMed Citation Articles by Larramendy-Gozalo, C. Articles by Deslys, J.-P. Agricola Articles by Larramendy-Gozalo, C. Articles by Deslys, J.-P.

Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases

¹ CEA, IMETI/SEPIA, 18 route du Panorama, BP6, 92265 Fontenay-aux-Roses cedex, France
² Laboratoire CRRET, CNRS FRE24-12, Université Paris XII-Val de Marne, Avenue du Général de Gaulle, 94010 Créteil, France
³ OTR3 Sarl, 4 Rue Française, 75001 Paris, France

Correspondence
Jean-Philippe Deslys
jpdeslys{at}cea.fr

Sulfated polyanions, including pentosan polysulfate (PPS) and heparan mimetics, number among the most effective drugs that have been used in experimental models of prion disease and are presumed to act in competition with endogenous heparan sulfate proteoglycans as co-receptors for prion protein (PrP) on the cell surface. PPS has been shown to prolong the survival of animals after intracerebral perfusion and is in limited use for the experimental treatment of human transmissible spongiform encephalopathies (TSEs). Here, PPS is compared with CR36, a new heparan mimetic. Ex vivo, CR36 was more efficient than PPS in reducing PrP^res in scrapie-infected cell cultures and showed long-lasting activity. In vivo, CR36 showed none of the acute toxicity observed with PPS and reduced PrP^res accumulation in spleens, but had only a marginal effect on the survival time of mice infected with bovine spongiform encephalopathy. In contrast, mice treated with PPS that survived the initial toxic mortality had no detectable PrP^res in the spleens and lived 185 days longer than controls (+55 %). These results show, once again, that anti-TSE drugs cannot be encouraged for human therapeutic trials solely on the basis of in vitro or ex vivo observations, but must first be subjected to in vivo animal studies.

This article has been cited by other articles:

				P. Brown Transmissible spongiform encephalopathy in the 21st century: Neuroscience for the clinical neurologist Neurology, February 26, 2008; 70(9): 713 - 722. [Full Text] [PDF]

				C. Riemer, M. Burwinkel, A. Schwarz, S. Gultner, S. W. F. Mok, I. Heise, N. Holtkamp, and M. Baier Evaluation of drugs for treatment of prion infections of the central nervous system J. Gen. Virol., February 1, 2008; 89(2): 594 - 597. [Abstract] [Full Text] [PDF]